ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
about
Quality markers in cardiology: measures of outcomes and clinical practice--a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular SurgeryReporting standards for guideline-based performance measuresThe Value of Medicines: A Crucial but Vague Concept.Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value.Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way to reduce price pressure.Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial.Current clinical management of pulmonary arterial hypertensionStrategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--EffectiveEvaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure.Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisIdentifying a "range of reasonable options" for cervical cancer screening.Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart FailureCost-Effectiveness of Ivabradine for Heart Failure in the United StatesCost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement.American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.Creation of the Prevention of Organ Failure Checklist. A Multidisciplinary Approach Using the Modified Delphi TechniqueComparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy ModelRelation between initial treatment strategy in stable coronary artery disease and 1-year costs in Ontario: a population-based cohort studyCost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.Value as the key concept in the health care system: how it has influenced medical practice and clinical decision-making processes.The Impact of Cryoballoon Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation on Healthcare Utilization and Costs: An Economic Analysis From the FIRE AND ICE Trial.Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.Cholesterol Management in the Era of PCSK9 Inhibitors.Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.The transition to value-based care.Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System.PCSK9 inhibitors: A new era of lipid lowering therapy.Cost Effectiveness of Implantable Cardiac Monitor-Guided Intermittent Anticoagulation for Atrial Fibrillation: An Analysis of the REACT.COM Pilot Study.Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model.Exploring Value in Congenital Heart Disease: An Evaluation of Inpatient Admissions.The lag from FDA approval to published cost-utility evidence.Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study.The Core Value of Cost-Effectiveness Analyses.Championing Effectiveness Before Cost-Effectiveness.Transcatheter aortic valve implantation economics: a grisly reality.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.
P2860
Q26778567-95C7292A-AF4B-4222-872D-75E00B17B7B2Q28067603-4737D2F2-60FD-4F79-8E30-5CBDF724DA00Q30248857-3B6E9D4A-0DF9-4E52-B9F8-164A300099C6Q31141584-2E0F9D1F-8DA3-4507-848E-8826127A548AQ34010544-0F975FED-73E5-42FB-95BF-73B552D3535BQ35114977-DEFFD53B-A499-4E66-A278-15ADC6C8055EQ35673783-89D931E7-F7C3-4402-ACDE-6452D9720221Q35793619-1875AFD5-8513-4967-B72D-6FE7A7AB7648Q35883256-56A7209D-6BC2-43D9-9B7E-5D7EAD914529Q36400944-A7A5F450-F508-4FA6-95DA-F356F4D110FEQ36483052-4818EA9B-E6D9-4DD2-814C-953623A23896Q36853325-CD7EE5C9-A1EB-4579-8601-6DD8FBAE80DDQ36956750-A0561ADC-928B-49A2-B851-408DA08CE071Q37122825-5B560EC2-A5D0-4421-AC31-A8D81A16EE3BQ37240851-594C54CB-1510-4E85-86CC-4E0FC3E4F2E9Q37248001-B95C3361-A6F8-4C29-9243-D830CA2B527EQ37265528-EAE016EE-600E-499F-BB4E-188F615A95EBQ37306197-449D26CE-BC7C-427B-B021-7B21ECA47EA4Q37357439-825E0DB3-443A-4678-8E57-1307E21590CCQ37722702-41553E2E-4674-48A1-BCAB-363B1477AFE4Q38373211-1157D5FE-214A-41C6-BE4B-83951C264C7BQ38529659-4808DD23-49C0-407D-AAE0-234B4570B181Q38611655-77D8A88F-10C4-4077-BBB5-4130394555FBQ38612448-D68EFE51-57EF-460B-833F-8E109FCDDFCFQ38639580-A8D4971E-3717-421A-A946-B895FE9AA054Q38758788-BDB2035E-0509-4048-B9E6-69367D075F39Q38902166-4E6A9F3B-B904-44BC-B399-D98A2DF866ACQ38905068-FDB6C324-6F45-499F-88E6-5D7E7FD613FBQ38921111-73AE3222-BB52-4DB5-86E2-C2C4871BD074Q39176815-76CEF8E2-2CBF-49CC-AF81-9161C381C111Q39443618-69F5C09E-3C88-45AD-9B02-1A36A9FC5206Q40104177-5AE22314-D88B-4737-B77C-5C5DC4FEBFA0Q40685276-0354D9D2-72E3-4550-ACEC-19CB9A33A5E3Q41595205-480BB7BF-6EC1-4E73-BF9E-6AECC6D20941Q41629841-D22815FA-236C-448A-8C0E-E131F2354607Q42342395-28582868-15C7-4E49-8B0E-2F31E7E040A0Q42342401-862CA664-AD9C-410A-9BF6-89054AA79420Q44641193-8DFD504B-23CF-41DC-BB9F-18138E8DBA7CQ45059153-3BDC88A5-CBE9-4A3C-81A7-FE0AD80D2894Q46658026-23C948C0-0D0E-4088-AE96-60E1AD08684A
P2860
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
description
im Juni 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2014
@uk
name
ACC/AHA Statement on Cost/Valu ...... lines and Performance Measures
@en
ACC/AHA Statement on Cost/Valu ...... lines and Performance Measures
@nl
type
label
ACC/AHA Statement on Cost/Valu ...... lines and Performance Measures
@en
ACC/AHA Statement on Cost/Valu ...... lines and Performance Measures
@nl
prefLabel
ACC/AHA Statement on Cost/Valu ...... lines and Performance Measures
@en
ACC/AHA Statement on Cost/Valu ...... lines and Performance Measures
@nl
P2093
P50
P1476
ACC/AHA Statement on Cost/Valu ...... lines and Performance Measures
@en
P2093
Alice K. Jacobs
Jeffrey L. Anderson
Leslee J. Shaw
Mark A. Creager
Mark A. Hlatky
Paul A. Heidenreich
Paul G. Barnett
Raymond J. Gibbons
P304
P356
10.1016/J.JACC.2014.03.016
P407
P577
2014-06-01T00:00:00Z